Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis
For the present analysis, we focused only on patients with HF who had at their initial visit (i) a diagnosis of HF, based on symptoms and signs together with a raised N-terminal pro-brain natriuretic peptide (NT-proBNP) (≥400 ng/L) 4; (ii) LVEF ≥45%, corresponding to mild or no evidence of LVSD, as...
Saved in:
| Published in | ESC Heart Failure Vol. 10; no. 2; pp. 1492 - 1496 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
John Wiley & Sons, Inc
01.04.2023
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | For the present analysis, we focused only on patients with HF who had at their initial visit (i) a diagnosis of HF, based on symptoms and signs together with a raised N-terminal pro-brain natriuretic peptide (NT-proBNP) (≥400 ng/L) 4; (ii) LVEF ≥45%, corresponding to mild or no evidence of LVSD, as determined by echocardiography; and (iii) measurements of LVWT. HF, heart failure; LVEF, left ventricular ejection fraction; LVWT, left ventricular wall thickness; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure. <14 mm) Age at referral (years) 78 (72, 83) 78 (72, 83) 0.54 77 (72, 82) 78 (72, 83) 0.03 Male (%) 56 45 <0.0001 59 49 0.004 BMI (kg/m2) 28 (25, 33) 27 (24, 31) 0.003 28 (25, 32) 28 (24, 32) 0.11 SBP (mmHg) 148 (130, 167) 142 (126, 163) 0.001 148 (130, 171) 145 (128, 163) 0.057 SBP < 140 mmHg (%) 38 45 0.004 39 42 0.34 DBP (mmHg) 79 (69, 89) 77 (68, 89) 0.17 79 (69, 90) 78 (68, 89) 0.59 HR (BPM) 71 (60, 84) 72 (62, 84) 0.26 69 (60, 81) 72 (61, 84) 0.89 NYHA class III/IV 32 31 0.85 29 32 0.54 6MWT (m) 288 (120, 375) 300 (135, 360) 0.88 300 (147, 375) 288 (120, 375) 0.41 ECG Heart rate (bpm) 71 (60, 84) 72 (62, 84) 0.26 69 (60, 81) 71 (61, 8) 0.08 PR interval (ms) 172 (154, 198) 168 (151, 194) 0.04 169 (154, 202) 170 (152, 196) 0.63 QRS duration (ms) 98 (88, 116) 92 (84, 108) <0.0001 100 (88, 119) 94 (84, 110) 0.0001 NT-proBNP (ng/L) 1386 (778, 2558) 1244 (776, 2256) 0.02 1497 (811, 2675) 1286 (773, 2325) 0.04 Co-morbidities AF (%) 44 48 0.13 41 47 0.08 IHD (%) 33 34 0.44 37 33 0.27 History of hypertension (%) 52 44 0.002 55 48 0.02 Diabetes (%) 27 22 0.04 32 24 0.005 COPD (%) 8 9 0.20 8 9 0.64 Treatment at referral Loop diuretics (%) 72 65 0.002 71 68 0.26 Thiazide diuretics (%) 8 8 0.93 7 8 0.63 ACEi/ARB (%) 63 61 0.44 61 63 0.68 Beta blockers (%) 56 61 0.03 51 60 0.007 MRA (%) 12 10 0.16 12 11 0.46 Echocardiography LVEF (%) 54 (48, 60) 55 (49, 60) 0.39 53 (47, 59) 55 (49, 61) 0.06 LVEDD (cm, BSA indexed) 2.5 (2.2, 2.8) 2.6 (2.3, 2.9) <0.0001 2.5 (2.2, 2.8) 2.6 (2.3, 2.9) 0.001 LVESD (cm, BSA indexed) 1.7 (1.5, 2.0) 1.8 (1.6, 2.1) <0.01 1.8 (1.5, 2.1) 1.8 (1.5, 2.1) 0.35 LA diameter (cm, BSA indexed) 2.2 (1.8, 2.5) 2.1 (1.9, 2.4) 0.31 2.2 (1.9, 2.6) 2.2 (1.9, 2.4) 0.08 Any mitral regurgitation (%) 68 73 0.03 70 71 0.76 Mitral regurgitation >moderate (%) 10 11 0.75 12 10 0.33 Aortic root (cm) 3.3 (3.0, 3.6) 3.2 (2.9, 3.5) <0.001 3.3 (3.0, 3.6) 3.2 (2.9, 3.6) 0.25 Aortic velocity (m/s) 1.4 (1.1, 1.8) 1.3 (1.1, 1.6) <0.0001 1.4 (1.1, 1.8) 1.4 (1.1, 1.7) 0.24 Aortic velocity, <3 m/s (%) 94 96 94 95 Aortic velocity, 3–4 m/s (%) 4 2 0.02 4 3 0.47 Aortic velocity, >4 m/s (%) 2 1 2 1 Any aortic regurgitation (%) 34 33 0.68 34 33 0.75 Aortic regurgitation >moderate (%) 5 2 0.01 4 3 0.56 Continuous variables were analysed using a Mann–Whitney analysis and reported as median with 25th and 75th centiles. Categorical variables were analysed using Fisher's exact test and reported as percentages. 6MWT, 6-min walk test; ACEi, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blockers; BMI, body mass index; BPM, beats per minute; BPM, beats per minute; BSA, body surface area; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HR, heart rate; IHD, ischaemic heart disease; LA, left atrial; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVSD, left ventricular systolic dysfunction; MRA, mineral corticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Failure Association; SBP, systolic blood pressure. |
|---|---|
| AbstractList | For the present analysis, we focused only on patients with HF who had at their initial visit (i) a diagnosis of HF, based on symptoms and signs together with a raised N-terminal pro-brain natriuretic peptide (NT-proBNP) (≥400 ng/L) 4; (ii) LVEF ≥45%, corresponding to mild or no evidence of LVSD, as determined by echocardiography; and (iii) measurements of LVWT. HF, heart failure; LVEF, left ventricular ejection fraction; LVWT, left ventricular wall thickness; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure. <14 mm) Age at referral (years) 78 (72, 83) 78 (72, 83) 0.54 77 (72, 82) 78 (72, 83) 0.03 Male (%) 56 45 <0.0001 59 49 0.004 BMI (kg/m2) 28 (25, 33) 27 (24, 31) 0.003 28 (25, 32) 28 (24, 32) 0.11 SBP (mmHg) 148 (130, 167) 142 (126, 163) 0.001 148 (130, 171) 145 (128, 163) 0.057 SBP < 140 mmHg (%) 38 45 0.004 39 42 0.34 DBP (mmHg) 79 (69, 89) 77 (68, 89) 0.17 79 (69, 90) 78 (68, 89) 0.59 HR (BPM) 71 (60, 84) 72 (62, 84) 0.26 69 (60, 81) 72 (61, 84) 0.89 NYHA class III/IV 32 31 0.85 29 32 0.54 6MWT (m) 288 (120, 375) 300 (135, 360) 0.88 300 (147, 375) 288 (120, 375) 0.41 ECG Heart rate (bpm) 71 (60, 84) 72 (62, 84) 0.26 69 (60, 81) 71 (61, 8) 0.08 PR interval (ms) 172 (154, 198) 168 (151, 194) 0.04 169 (154, 202) 170 (152, 196) 0.63 QRS duration (ms) 98 (88, 116) 92 (84, 108) <0.0001 100 (88, 119) 94 (84, 110) 0.0001 NT-proBNP (ng/L) 1386 (778, 2558) 1244 (776, 2256) 0.02 1497 (811, 2675) 1286 (773, 2325) 0.04 Co-morbidities AF (%) 44 48 0.13 41 47 0.08 IHD (%) 33 34 0.44 37 33 0.27 History of hypertension (%) 52 44 0.002 55 48 0.02 Diabetes (%) 27 22 0.04 32 24 0.005 COPD (%) 8 9 0.20 8 9 0.64 Treatment at referral Loop diuretics (%) 72 65 0.002 71 68 0.26 Thiazide diuretics (%) 8 8 0.93 7 8 0.63 ACEi/ARB (%) 63 61 0.44 61 63 0.68 Beta blockers (%) 56 61 0.03 51 60 0.007 MRA (%) 12 10 0.16 12 11 0.46 Echocardiography LVEF (%) 54 (48, 60) 55 (49, 60) 0.39 53 (47, 59) 55 (49, 61) 0.06 LVEDD (cm, BSA indexed) 2.5 (2.2, 2.8) 2.6 (2.3, 2.9) <0.0001 2.5 (2.2, 2.8) 2.6 (2.3, 2.9) 0.001 LVESD (cm, BSA indexed) 1.7 (1.5, 2.0) 1.8 (1.6, 2.1) <0.01 1.8 (1.5, 2.1) 1.8 (1.5, 2.1) 0.35 LA diameter (cm, BSA indexed) 2.2 (1.8, 2.5) 2.1 (1.9, 2.4) 0.31 2.2 (1.9, 2.6) 2.2 (1.9, 2.4) 0.08 Any mitral regurgitation (%) 68 73 0.03 70 71 0.76 Mitral regurgitation >moderate (%) 10 11 0.75 12 10 0.33 Aortic root (cm) 3.3 (3.0, 3.6) 3.2 (2.9, 3.5) <0.001 3.3 (3.0, 3.6) 3.2 (2.9, 3.6) 0.25 Aortic velocity (m/s) 1.4 (1.1, 1.8) 1.3 (1.1, 1.6) <0.0001 1.4 (1.1, 1.8) 1.4 (1.1, 1.7) 0.24 Aortic velocity, <3 m/s (%) 94 96 94 95 Aortic velocity, 3–4 m/s (%) 4 2 0.02 4 3 0.47 Aortic velocity, >4 m/s (%) 2 1 2 1 Any aortic regurgitation (%) 34 33 0.68 34 33 0.75 Aortic regurgitation >moderate (%) 5 2 0.01 4 3 0.56 Continuous variables were analysed using a Mann–Whitney analysis and reported as median with 25th and 75th centiles. Categorical variables were analysed using Fisher's exact test and reported as percentages. 6MWT, 6-min walk test; ACEi, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blockers; BMI, body mass index; BPM, beats per minute; BPM, beats per minute; BSA, body surface area; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HR, heart rate; IHD, ischaemic heart disease; LA, left atrial; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVSD, left ventricular systolic dysfunction; MRA, mineral corticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Failure Association; SBP, systolic blood pressure. |
| Author | Cleland, John G.F. Kazmi, Syed Sarna, Harpreet S. Brownrigg, Jack Araghi, Marzieh Leo, Vincenzo C. Clark, Andrew L. Cuthbert, Joe Pellicori, Pierpaolo |
| AuthorAffiliation | 4 Hull York Medical School Castle Hill Hospital Castle Rd, Cottingham Kingston upon Hull HU16 5JQ UK 2 Hull University Teaching Hospitals Trust, Castle Hill Hospital Castle Rd Cottingham HU16 5JQ UK 1 Pfizer Ltd, Walton Oaks Dorking Rd Tadworth KT20 7NS UK 3 British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health University of Glasgow Glasgow UK G12 8QQ |
| AuthorAffiliation_xml | – name: 1 Pfizer Ltd, Walton Oaks Dorking Rd Tadworth KT20 7NS UK – name: 3 British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health University of Glasgow Glasgow UK G12 8QQ – name: 2 Hull University Teaching Hospitals Trust, Castle Hill Hospital Castle Rd Cottingham HU16 5JQ UK – name: 4 Hull York Medical School Castle Hill Hospital Castle Rd, Cottingham Kingston upon Hull HU16 5JQ UK |
| Author_xml | – sequence: 1 givenname: Vincenzo C. surname: Leo fullname: Leo, Vincenzo C. organization: Pfizer Ltd, Walton Oaks – sequence: 2 givenname: Syed surname: Kazmi fullname: Kazmi, Syed organization: Hull University Teaching Hospitals Trust, Castle Hill Hospital – sequence: 3 givenname: Jack surname: Brownrigg fullname: Brownrigg, Jack organization: Pfizer Ltd, Walton Oaks – sequence: 4 givenname: Marzieh surname: Araghi fullname: Araghi, Marzieh email: marzieh.araghi@pfizer.com organization: Pfizer Ltd, Walton Oaks – sequence: 5 givenname: Harpreet S. surname: Sarna fullname: Sarna, Harpreet S. organization: Pfizer Ltd, Walton Oaks – sequence: 6 givenname: Pierpaolo surname: Pellicori fullname: Pellicori, Pierpaolo organization: University of Glasgow – sequence: 7 givenname: Joe surname: Cuthbert fullname: Cuthbert, Joe organization: Hull York Medical School Castle Hill Hospital – sequence: 8 givenname: John G.F. surname: Cleland fullname: Cleland, John G.F. organization: University of Glasgow – sequence: 9 givenname: Andrew L. surname: Clark fullname: Clark, Andrew L. organization: Hull University Teaching Hospitals Trust, Castle Hill Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36811158$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ksFu3CAQQK0qVZOmufQDKku9VJU2ZQZj41NVRZsmUqReckcshl1WNjiAG_nvy67TKOmhJ2B4PGZg3hcnzjtdFB-BXAIh-E3vDF5CRYG9Kc6QMLZiHPHkxfy0uIhxTwgBVgPD6l1xSmsOAIyfFX4dkx1ksm5bukn1WoYyKuncIaDkKJVNcxn0w2SDHrRLsTQ-lGM-cVw82rQr4xRHrZLu8onQWanKFKSLaTcHnc2lHObe285HGz8Ub43so754Gs-L--v1_dXN6u7Xz9urH3crVTUVW3GG3BhNEaFCjnzTqE1tCNaaSqi7rkbsGkbrvFZoeIsVJYoq3upNI42k58Xtou283Isx5BLDLLy04hjwYStkSDbXKxqCRpquBQO0aqHlHJuqMZxpBaRmkF3fF9c4bQbdqVx3kP0r6esdZ3di63-L_D-MAifZ8OXJEPzDpGMSg41K97102k9RYNO0lAEHzOjnf9C9n4LLT5WpnB0gw4Pw60Kp4GMM2jxnA-RwLYpDW4hjW2T408v8n9G_TZABWIBH2-v5PyqxvrnGRfoHjqDE7w |
| Cites_doi | 10.1016/j.jchf.2019.04.010 10.1093/eurheartj/ehab072 10.1002/ehf2.13961 10.1016/j.jacc.2019.09.056 10.1586/erc.10.41 10.1093/eurheartj/ehv338 10.1038/s41598-018-19507-7 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. – notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1002/ehf2.14315 |
| DatabaseName | Wiley-Blackwell Open Access Collection Wiley Online Library Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley-Blackwell Open Access Collection url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 7X7 name: Health & Medical Collection (Proquest) url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Letter to the Editor |
| EISSN | 2055-5822 |
| EndPage | 1496 |
| ExternalDocumentID | oai_doaj_org_article_702fafd91f134919882747f85ec10651 10_1002_ehf2_14315 36811158 EHF214315 |
| Genre | letter Letter Research Support, Non-U.S. Gov't Correspondence |
| GrantInformation_xml | – fundername: Pfizer – fundername: ; |
| GroupedDBID | 0R~ 1OC 24P 53G 5VS 7X7 8FI 8FJ AAHHS ABUWG ACCFJ ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AEQDE AFKRA AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD EMOBN FYUFA GODZA GROUPED_DOAJ HMCUK HYE IAO IHR INH KQ8 M~E OK1 PIMPY PQQKQ PROAC RPM UKHRP WIN CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c4745-8528ffe322142828b7cb6f026e3a16dd622d75366e3c2f892430c3c89eb7afa3 |
| IEDL.DBID | RPM |
| ISSN | 2055-5822 |
| IngestDate | Tue Oct 22 15:00:58 EDT 2024 Tue Sep 17 21:35:14 EDT 2024 Sat Oct 05 06:18:36 EDT 2024 Thu Oct 10 16:07:41 EDT 2024 Thu Sep 26 19:06:19 EDT 2024 Sat Sep 28 08:20:55 EDT 2024 Sat Aug 24 00:56:43 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | Attribution-NonCommercial This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4745-8528ffe322142828b7cb6f026e3a16dd622d75366e3c2f892430c3c89eb7afa3 |
| Notes | SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Correspondence-1 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053180/ |
| PMID | 36811158 |
| PQID | 2791912520 |
| PQPubID | 4368362 |
| PageCount | 1496 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_702fafd91f134919882747f85ec10651 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10053180 proquest_miscellaneous_2779351812 proquest_journals_2791912520 crossref_primary_10_1002_ehf2_14315 pubmed_primary_36811158 wiley_primary_10_1002_ehf2_14315_EHF214315 |
| PublicationCentury | 2000 |
| PublicationDate | April 2023 |
| PublicationDateYYYYMMDD | 2023-04-01 |
| PublicationDate_xml | – month: 04 year: 2023 text: April 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford – name: Hoboken |
| PublicationTitle | ESC Heart Failure |
| PublicationTitleAlternate | ESC Heart Fail |
| PublicationYear | 2023 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | e_1_2_1_4_4_1 e_1_2_1_4_6_1 e_1_2_1_4_7_1 e_1_2_1_4_9_1 e_1_2_1_4_8_1 e_1_2_1_4_10_1 Al‐Mohammad A (e_1_2_1_4_5_1) 2018; 362 e_1_2_1_4_2_1 e_1_2_1_4_3_1 |
| References_xml | – ident: e_1_2_1_4_4_1 doi: 10.1016/j.jchf.2019.04.010 – ident: e_1_2_1_4_6_1 doi: 10.1093/eurheartj/ehab072 – ident: e_1_2_1_4_9_1 doi: 10.1002/ehf2.13961 – ident: e_1_2_1_4_10_1 doi: 10.1016/j.jacc.2019.09.056 – ident: e_1_2_1_4_2_1 doi: 10.1586/erc.10.41 – volume: 362 year: 2018 ident: e_1_2_1_4_5_1 article-title: Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance publication-title: BMJ contributor: fullname: Al‐Mohammad A – ident: e_1_2_1_4_3_1 doi: 10.1093/eurheartj/ehv338 – ident: e_1_2_1_4_7_1 – ident: e_1_2_1_4_8_1 doi: 10.1038/s41598-018-19507-7 |
| SSID | ssj0001561524 |
| Score | 2.2622356 |
| Snippet | For the present analysis, we focused only on patients with HF who had at their initial visit (i) a diagnosis of HF, based on symptoms and signs together with a... |
| SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1492 |
| SubjectTerms | Amyloid Neuropathies, Familial - diagnosis Amyloidosis Blood pressure Body mass index Chronic obstructive pulmonary disease Diabetes Diuretics Ejection fraction Heart Heart failure Heart rate Humans Hypertension Letter to the Editor Letters to the Editor Peptides Scintigraphy Velocity |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PT9swFH6aOKBdJmA_CIPJ0zghRSSOnbhHQK2qSezEJG6W4x_QAylq2v9_79lp1WoILtzSxFVdf35-3-fYnwHOkQHLVqJSVc7xXHhb5C3m_dwoYUpbWiMq2ih8-6ee_hW_7-X91lFftCYs2QOnhrtsCh5McKMykJEeSmRFOioo6S2qGZmETzHaElPD_mBMTGLjR8ov_WPgOCxUdP7tVgaKRv0vscv_F0luk9eYfSYH8GmgjewqVfcQPvjuCPZvhxfjn2E-xlAl8tk9sI4sis2C9TadR8QsJkSLbJstPK37jROCPUO2ygZX1Z7RdCzrV3HfpXf4Deo3li0pkyGUtNWxY-YJ1f3MzftZ_wXuJuO7m2k-nKWQW9EImSvJVQgew5cs1rhqG9vWAQWYr0xZO1dz7hC3Gj9bHhSqsqqwlVUj3zYmmOor7HXzzh8DKxxmO26FVM6KQljjMOSbBqVQM6qD4Rn8Wjevfk6OGTp5I3NNIOgIQgbX1PKbEuRyHW8g9nrAXr-FfQana9z0EHq95g2WRNrGiwx-bh5j0NCbENP5-YrK4LAkidxk8C3BvKlJVSsc_6XKQO10gJ2q7j7pZo_RmLuMQ5rCH76IfeWV_6_H0wmPVyfv0RLf4SNH9pWWFJ3C3nKx8mfIlpbtjxgY_wD6FRGN priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swEBZbCmMvo91Pt13R2J4GpvZZsuWnso6EMGgZo4O-GVk_2jzU7uLk_9-drKQNG32LY4fYvjvd952k7xj7gghYthKZqrIWUuFMlraY91OthM5NbrQoaKPwxWU5_y1-XMvrWHAb4rLKzZgYBmrbG6qRn0JVI7UACdnZ_Z-UukbR7GpsofGc7QEyBZiwvfPp5c9fD1UWhAcSxFaXFE7drQccHgrqg_soEwXB_v-hzH8XSz4GsSELzfbZqwgf-bfR3gfsmetesxcXcYL8DeunGLIEQrsb3pFUsV7ywYx9ibjBxGgQdfOlo_W_oTA4cEStPKqrDpzKsnxYh_2XzuIvyH8MX1FGQ5PSlseO6ztk-QvbD4vhLbuaTa--z9PYUyE1ohIyVRKU9w7DmKTWQLWVaUuPRMwVOi-tLQEs2q_EYwNeITsrMlMYVbu20l4X79ik6zv3gfHMYtYDI6SyRmTCaIuhX1VIiaq69BoS9nnzepv7UTmjGTWSoSEjNMEICTunN7-9gtSuwxf98qaJwdNUGXjtbZ17ElPMa2QFyIK8ks4go5V5wo43dmtiCA7Ng8Mk7NP2NAYPzYjozvVrugaHJ0kgJ2HvRzNv76QoFeYBqRKmdhxg51Z3z3SL2yDQnYehTeEffw2-8sTzN9P5DMKnw6cf4oi9pE7346KhYzZZLdfuI-KhVXsSnf4vR74LqQ priority: 102 providerName: ProQuest – databaseName: Wiley-Blackwell Open Access Collection dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Na9wwEB1CCqWXkn47SYtCeyqY2GPJ1kIubdllCaT0kEJuRtZHsofaZb37_zsje71dWgq92ZaMbY2e5o2seQL4QAxYNYoiVe0cptLbLG3I76dGS5Pb3BpZcKLwzddy-V1e36m7I7ja5cIM-hDThBsjI47XDHDT9Jd70VD_EJBwXnCG-SOWjOH-jfLbfoaFqIGKu9piplSqyBVO-qR4ub_9wCNF4f6_sc0_F03-TmajN1qcwNORRopPg92fwZFvn8Pjm_FH-Qvo5gRdJqPtvWhZstisRW-H_YmEJQdpiX2Lted1wHGCsBfEXsWostoLnp4V_TbmYXpHd3A_smLDno1My6mPrTA_KNpfua5f9S_hdjG__bJMx70VUisrqVKtUIfgCc4suYa6qWxTBgrIfGHy0rkS0ZEdSzq3GDRFaUVmC6tnvqlMMMUrOG671r8BkTnyfmil0s7KTFrjaAioKgqNqlkZDCbwfte89c9BQaMetJKxZiPU0QgJfOaWn2qw6nW80K3v6xFEdZVhMMHN8sCiivmMogOKhoJW3lJkq_IEznd2q0co9jVWVJNoHGYJXEzFBCL-M2Ja3225Dg1TislOAq8HM09vUpSa_IHSCeiDDnDwqocl7eohCnXncYjT9OCPsa_84_vr-XKB8ej0fyqfwRMk1jUsJTqH4816698SS9o07yIYfgFH8gyn priority: 102 providerName: Wiley-Blackwell |
| Title | Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fehf2.14315 https://www.ncbi.nlm.nih.gov/pubmed/36811158 https://www.proquest.com/docview/2791912520 https://search.proquest.com/docview/2779351812 https://pubmed.ncbi.nlm.nih.gov/PMC10053180 https://doaj.org/article/702fafd91f134919882747f85ec10651 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED6aFsZeytb9qLcuaGxPAze2LFnK41oSwiAljA7yZmT9aAONXeLk_99JtkPCxh72EpJYwYrvzvd98t0ngK-IgHnJkalKY2jMrE7iEvN-rCRTqU61YplvFJ7f5bNf7MeSL08g73thQtG-LlfX1dP6ulo9htrK57Ue9XVio8X8Ng2uI5PRAAbooQccvesNxqTE9lqkdGQfHcVbQpb6fWqyXGJ8-y3eDxJR0Ov_G8j8s1byEMOGJDR9BecdeiTf21m-hhNbXcCLefd8_A3UE4xYj0GrB1J5pWK1IY1utyUiGvOiRtBNNtaX_4Z1wYYgaCWduGpD_KosaXah_dIa_IV3H022PqGhRX3HY0XUGkn-ytTNqnkL99PJ_e0s7rZUiDUTjMeSU-mcxSj2SmtUlkKXuUMeZjOV5sbklBo0X46fNXUSyVmW6EzLsS2Fcip7B6dVXdlLIInBpEc149JoljCtDEa-EMiIxDh3ikbwpb-8xXMrnFG0Esm08PYogj0iuPFXfj_Ci12HL-rNQ9GZvBAJdcqZceq8lmI6RlKAJMhJbjUSWp5GcNXbregisCmowJGI3mgSwef9YYwd_0BEVbbe-TF4d-Ie40TwvjXzfia9m0QgjxzgaKrHR9Bdgz53754RfAu-8o__X0xmUxreffj_83yElxShV1tPdAWn283OfkKotC2HMKBsga9iKYZwdjO5W_wchmWHYYiZ37F9F9w |
| link.rule.ids | 230,315,730,783,787,867,888,2109,11576,12070,21402,27938,27939,31733,31734,33758,33759,43324,43819,46066,46490,50828,50937,53806,53808,74081,74638 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkYAL4rkEFjCCE1K0iWPHzgkBalVgu6ci9WY5fuz2QLI07f9nxnG7W4H2lqfymNc3Y_sbQj4CAhatgExVOcdy7m2RtxD3c6O4KW1pDa9wofD8vJ794j-WYpkKbkOaVrnzidFRu95ijfyUyQZSCyZY8fnqT45do3B0NbXQuEvuIQ8XcufLpbyusQA4EIzvWUnZqb8MDJxDhV1wb8ShSNf_P4z571TJmxA2xqDpY_IogUf6ZZT2E3LHd0_J_XkaHn9G-gkYLELQ7oJ2SFRs1nSwY1ciaiEsWsDcdO1x9m8sCw4UMCtN3KoDxaIsHbZx9aV3cAdqj6UbjGcgUFzw2FHzG3L8leuH1fCcLKaTxbdZnjoq5JZLLnIlmArBgxEj0RpTrbRtHSAN85Upa-dqxhxIr4Z9y4KC3KwqbGVV41tpgqlekKOu7_xLQgsHMY9ZLpSzvODWODB8KSEhkk0dDMvIh93v1Vcjb4YeGZKZRiHoKISMfMU_v78Cua7jgX59oZPpaFmwYIJryoBUimUDOQHkQEEJbyGfFWVGTnZy08kAB32tLhl5vz8NpoPjIabz_RavAeckEOJk5HgU8_5NqlpBFBAqI-pAAQ5e9fBMt7qM9NxldGwKHvwp6sot368nsymLW69u_4h35MFsMT_TZ9_Pf74mD7Hn_Th96IQcbdZb_waQ0aZ9G9X_L4iNDTQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFLagSBUXxE5KASM4IUWTOHbsnBDLjIalFYcizc1yvLRzICmTmf_f9xzPtCNQb1mV5W3fs5-_R8h7QMCiFZCpKudYzr0t8hbifm4UN6UtreEVLhQ-Oa3nv_n3hVik-qchlVVufWJ01K63OEY-YbKB1IIJVkxCKov49XX28fJvjh2kcKY1tdO4S-5JDoEOdFsu5PV4CwAFwfiOoZRN_EVg4Cgq7Ih7IyZF6v7_4c1_yyZvwtkYj2YPyYMEJOmnUfKPyB3fPSaHJ2mq_Anpp2C8CEe7c9ohabFZ0cGOHYqohRBpAX_TlcdK4DhEOFDArzTxrA4UB2jpsIkrMb2DO1CTLF1jbAPh4uLHjpo_kO8vXT8sh6fkbDY9-zLPU3eF3HLJRa4EUyF4MGgkXWOqlbatA6RkvjJl7VzNmANJ1rBvWVCQp1WFraxqfCtNMNUzctD1nX9BaOEg_jHLhXKWF9waB05ASkiOZFMHwzLybvt79eXIoaFHtmSmUQg6CiEjn_HP765A3ut4oF-d62RGWhYsmOCaMiCtYtlAfgD5UFDCW8htRZmR463cdDLGQV-rTkbe7k6DGeHciOl8v8FrwFEJhDsZeT6KefcmVa0gIgiVEbWnAHuvun-mW15Equ4yOjkFD_4QdeWW79fT-YzFraPbP-INOQTN1z-_nf54Se4zAF1jJdExOVivNv4VgKR1-zpq_xUeohFp |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimating+nuclear+scanning+capacity+requirements+for+patients+with+suspected+cardiac+transthyretin+amyloidosis&rft.jtitle=ESC+Heart+Failure&rft.au=Leo%2C+Vincenzo+C.&rft.au=Kazmi%2C+Syed&rft.au=Brownrigg%2C+Jack&rft.au=Araghi%2C+Marzieh&rft.date=2023-04-01&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2055-5822&rft.volume=10&rft.issue=2&rft.spage=1492&rft.epage=1496&rft_id=info:doi/10.1002%2Fehf2.14315&rft_id=info%3Apmid%2F36811158&rft.externalDBID=PMC10053180 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2055-5822&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2055-5822&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2055-5822&client=summon |